Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05987592 · ClinicalTrials.gov registry record · NA
BE WELL With Migraine: Brain Education and WELLness With Migraine
A NA study of Migraine, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 286
- Enrollment target
- 3
- Study locations
NCT05987592: Recruiting NA study of Migraine, sponsored by Wake Forest University Health Sciences.
NCT05987592 is a NA study of Migraine that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 286 participants, below the 355-participant average among 102 other Migraine trials with a reported enrollment target (19% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05987592, a NA study of Migraine, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 286 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.
Primary Outcome
Most frequently used headache disability measure developed by Dr. Richard Lipton that captures both presenteeism and absenteeism. Although originally developed to report the prior 3 months, the monthly MIDAS ("mMIDAS") reduces recall bias and improves validity.
Conditions Studied
Interventions
- BEHAVIORAL Brain Education and WELLness with Migraine Group A
- BEHAVIORAL Brain Education and WELLness with Migraine Group B
Study Locations (3)
Massachusetts
- Cambridge Health Alliance - Center for Mindfulness and Compassion - Cambridge
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05987592 shows while recruiting
NCT05987592 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, below the 355-participant average among 102 other Migraine trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Brain Education and WELLness with Migraine Group A is the first listed.
NCT05987592 reports a single indexed study location in Massachusetts, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT05987592 about?
NCT05987592 is a clinical study titled "BE WELL With Migraine: Brain Education and WELLness With Migraine". The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all ...
What is the current status of trial NCT05987592?
This trial is currently recruiting. It is a NA study. The enrollment target is 286 participants. The study started on 2024-07-31. Estimated completion is 2027-06-30.
What conditions does trial NCT05987592 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05987592?
The interventions under investigation include: Brain Education and WELLness with Migraine Group A (BEHAVIORAL), Brain Education and WELLness with Migraine Group B (BEHAVIORAL).
Who is sponsoring clinical trial NCT05987592?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05987592 being conducted?
This trial has 3 study locations across Massachusetts, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05987592's enrollment target sits among peer trials
286 34th of 102 higher than 69 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI